DOCSLIB.ORG

X]*Premenstrual Dysphoric Disorder K584.00 Premenstrual Tension Syndrome *[X] Implies a Code Cross References to a Specific ICD10 Code

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
X]*Premenstrual Dysphoric Disorder K584.00 Premenstrual Tension Syndrome *[X] Implies a Code Cross References to a Specific ICD10 Code Table S1 List of diagnostic codes included in the study. Read code Description Eu3y200 [X]*Premenstrual dysphoric disorder K584.00 Premenstrual tension syndrome *[X] implies a code cross references to a specific ICD10 code Table S2 List of drugs included in the prescription analysis, by drug category. BNF code Drug name Category 09.06.02.00 Pyridoxine 50mg capsule Vitamin B6 09.06.02.00 Pyridoxine 10mg tablets Vitamin B6 09.06.02.00 Pyridoxine 20mg tablets Vitamin B6 09.06.02.00 Pyridoxine 10mg tablets Vitamin B6 09.06.02.00 Pyridoxine 100mg tablets Vitamin B6 09.06.02.00 Pyridoxine 50mg tablets Vitamin B6 09.06.02.00 Pyridoxine 50mg tablets Vitamin B6 09.06.02.00 VITAMIN B 6 100 MG TAB Vitamin B6 09.06.02.00 PYRIDOXINE 50 MG INJ Vitamin B6 09.06.02.00 Vitamin b compound strong syrup Vitamin B6 09.06.02.00 Pyridoxine 50mg tablets Vitamin B6 09.06.02.00 Pyridoxine 20mg tablets Vitamin B6 09.06.02.00 Pyridoxine 50mg tablets Vitamin B6 09.06.02.00 Pyridoxine 20mg tablets Vitamin B6 09.06.02.00 Pyridoxine 50mg tablets Vitamin B6 09.06.02.00 Pyridoxine 10mg tablets Vitamin B6 09.06.02.00 PYRIDOXINE 20mg tablets Vitamin B6 09.06.02.00 PYRIDOXINE HCL 100mg m/r tabs Vitamin B6 09.06.02.00 Pyridoxine 50mg tablets Vitamin B6 09.06.02.00 Pyridoxine 10mg tablets Vitamin B6 09.06.02.00 Pyridoxine 20mg tablets Vitamin B6 09.06.02.00 VITAMIN B 6 50 MG TAB Vitamin B6 09.06.02.00 Pyridoxine 100mg modified release tablet Vitamin B6 09.06.02.00 Pyridoxine 10mg tablets Vitamin B6 09.06.02.00 PYRIDOXINE 50mg tablets Vitamin B6 06.07.02.00 Danazol 200mg capsules Danazol 06.07.02.00 Danazol 200mg capsules Danazol 06.07.02.00 Danazol 200mg capsules Danazol 06.07.02.00 Danazol 100mg capsules Danazol 06.07.02.00 DANAZOL 100mg capsules Danazol 06.07.02.00 DANAZOL 200mg capsules Danazol 06.07.02.00 Danazol 100mg capsules Danazol 06.07.02.00 Nafarelin 200micrograms/dose nasal spray Gonadotrophins 06.07.02.00 NAFARELIN NASAL 2 MG/ML SPR Gonadotrophins 06.07.02.00 NAFARELIN 200mcg nasal spray Gonadotrophins Leuprorelin 3.75mg Powder for solution for 08.03.04.02 injection Gonadotrophins 08.03.04.02 Cyproterone 100mg tablets Gonadotrophins 08.03.04.02 CYPROTERONE ACETATE 100mg tabs Gonadotrophins Leuprorelin 3.75mg powder and solvent for 08.03.04.02 suspension for injection pre-filled syringes Gonadotrophins 08.03.04.02 BUSERELIN 5.5mg/5.5mL inj Gonadotrophins 08.03.04.02 GOSERELIN 3.6mg implant Gonadotrophins 08.03.04.02 Flutamide 250mg tablets Gonadotrophins 08.03.04.02 Cyproterone 100mg tablets Gonadotrophins Leuprorelin 3.75mg powder and solvent for 08.03.04.02 suspension for injection vials Gonadotrophins 08.03.04.02 LEUPRORELN ACETATE 11.25mg inj Gonadotrophins 08.03.04.02 Flutamide 250mg tablets Gonadotrophins 08.03.04.02 Buserelin 100micrograms/dose nasal spray Gonadotrophins Leuprorelin 11.25mg powder and solvent for 08.03.04.02 suspension for injection pre-filled syringes Gonadotrophins 08.03.04.02 Cyproterone 50mg tablets Gonadotrophins 08.03.04.02 LEUPRORELIN ACETATE 3.75mg inj Gonadotrophins 08.03.04.02 Flutamide 250mg tablets Gonadotrophins 08.03.04.02 GOSERELIN 10.8mg implant Gonadotrophins 08.03.04.02 LEUPRORELIN ACET 11.25mg inj Gonadotrophins 08.03.04.02 LEUPRORELIN 3.75mg injection Gonadotrophins 08.03.04.02 FLUTAMIDE 250mg tablets Gonadotrophins 08.03.04.02 BUSERELIN 100mcg nasal spray Gonadotrophins 08.03.04.02 BICALUTAMIDE 50mg tablets Gonadotrophins 08.03.04.02 Cyproterone 50mg tablets Gonadotrophins 08.03.04.02 BICALUTAMIDE 150mg tablets Gonadotrophins 08.03.04.02 Flutamide 250mg tablets Gonadotrophins 08.03.04.02 GOSERELIN 3.6mg implant Gonadotrophins 08.03.04.02 FLUTAMIDE 250mg tablets Gonadotrophins 08.03.04.02 CYPROTERONE 50mg tablets Gonadotrophins 08.03.04.02 CYPROTERONE 50mg tablets Gonadotrophins 08.03.04.02 CYPROTERONE ACETATE 100mg tabs Gonadotrophins 08.03.04.02 Bicalutamide 50mg tablets Gonadotrophins 08.03.04.02 Bicalutamide 50mg tablets Gonadotrophins 08.03.04.02 Cyproterone 50mg tablets Gonadotrophins 08.03.04.02 GOSERELIN 10.8mg implant Gonadotrophins 08.03.04.02 LEUPRORELIN ACETATE 3.75mg inj Gonadotrophins Leuprorelin 11.25mg Powder for solution for 08.03.04.02 injection Gonadotrophins 08.03.04.02 Bicalutamide 150mg tablets Gonadotrophins 08.03.04.02 Goserelin 10.8mg implant pre-filled syringes Gonadotrophins 08.03.04.02 Cyproterone 50mg tablets Gonadotrophins 08.03.04.02 Cyproterone 100mg tablets Gonadotrophins 08.03.04.02 Leuprorelin 11.25mg powder and solvent for Gonadotrophins suspension for injection vials 08.03.04.02 Goserelin 3.6mg implant pre-filled syringes Gonadotrophins 08.03.04.02 Cyproterone 50mg tablets Gonadotrophins 08.03.04.02 Abiraterone 250mg tablets Gonadotrophins 08.03.04.02 Buserelin 5.5mg/5.5ml solution for injection vials Gonadotrophins 08.03.04.02 Histrelin 50mg implant with device Gonadotrophins 06.04.02.00 CYPROTERONE ACETATE 50mg tabs Gonadotrophins Triptorelin acetate 3.75mg powder and solvent for suspension for injection pre-filled disposable 06.07.02.00 devices Gonadotrophins Triptorelin acetate 11.25mg powder and solvent 06.07.02.00 for suspension for injection vials Gonadotrophins 06.07.02.00 TRIPTORELIN 3.75mg inj syringe Gonadotrophins 06.07.02.00 TRIPTORELIN 22.5mg inj pdr Gonadotrophins 06.07.02.00 TRIPTORELIN 11.25mg injection Gonadotrophins 06.07.02.00 TRIPTORELIN 11.25mg inj powder Gonadotrophins Triptorelin embonate 11.25mg powder and solvent 06.07.02.00 for suspension for injection vials Gonadotrophins 06.07.02.00 Buserelin 150micrograms/dose nasal spray Gonadotrophins Triptorelin acetate 3mg powder and solvent for 06.07.02.00 suspension for injection vials Gonadotrophins 06.07.02.00 TRIPTORELIN 3mg inj powder Gonadotrophins 06.07.02.00 Buserelin 150micrograms spray Gonadotrophins Triptorelin embonate 22.5mg powder and solvent 06.07.02.00 for suspension for injection vials Gonadotrophins 06.07.02.00 BUSERELIN 5.5mg/5.5mL inj Gonadotrophins 06.04.01.01 Estradiol acetate 1.25mg vaginal ring Oestrogen 06.04.01.01 ESTRADIOL 0.5mg/dose gel Oestrogen 06.04.01.01 Estradiol 25mg implant Oestrogen 06.04.01.01 ESTRADIOL 80mcg patches Oestrogen CONJUGATED OESTROGENS 625/NORGESTREL 500 06.04.01.01 MCG TAB Oestrogen 06.04.01.01 PIPERAZINE ESTRONE 1.5mg tabs Oestrogen 06.04.01.01 ESTRADIOL 100mcg patches Oestrogen 06.04.01.01 ESTRADIOL 50micrograms patches Oestrogen 06.04.01.01 Ethinylestradiol 10microgram tablets Oestrogen Estradiol and (estradiol with levonorgestrel) 50mcg/24hrs with (50mcg+10mcg/24hrs) once 06.04.01.01 weekly patch Oestrogen 06.04.01.01 Estradiol 25micrograms/24hr twice weekly patch Oestrogen 06.04.01.01 ESTRADIOL 75micrograms patches Oestrogen 06.04.01.01 Estradiol 100micrograms/24hr twice weekly patch Oestrogen 06.04.01.01 Estradiol with estrone and estriol tablets Oestrogen 06.04.01.01 ESTRADIOL 75micrograms patches Oestrogen 06.04.01.01 ESTRADIOL VALERATE 1mg tablets Oestrogen 06.04.01.01 OESTRADIOL 1 MG TAB Oestrogen 06.04.01.01 Estradiol 75micrograms/24hr twice weekly patch Oestrogen Estradiol 100micrograms/24hours transdermal 06.04.01.01 patches Oestrogen 06.04.01.01 Estradiol 100micrograms/24hr once weekly patch Oestrogen Estradiol 25micrograms/24hours transdermal 06.04.01.01 patches Oestrogen 06.04.01.01 Estradiol 100mg implant Oestrogen Estradiol 100micrograms/24hours transdermal 06.04.01.01 patches Oestrogen Estradiol 100micrograms/24hours transdermal 06.04.01.01 patches Oestrogen 06.04.01.01 ESTRADIOL 100mcg patches Oestrogen 06.04.01.01 Estradiol 25micrograms/24hr twice weekly patch Oestrogen 06.04.01.01 ESTRADIOL 100mcg patches Oestrogen 06.04.01.01 ESTRADIOL 50micrograms patches Oestrogen 06.04.01.01 ESTRADIOL VALERATE 2mg tablets Oestrogen 06.04.01.01 ESTRIOL 250mcg tablets Oestrogen 06.04.01.01 ESTRADIOL 1mg/dose gel Oestrogen Ethinylestradiol with methyltestosterone 06.04.01.01 4.4micrograms + 3.6mg Tablet Oestrogen 06.04.01.01 OESTRADIOL SKIN PATCHES 50MCG Oestrogen 06.04.01.01 Estradiol 50micrograms/24hr once weekly patch Oestrogen 06.04.01.01 TRANSDERMAL OESTRADIOL 50 MCG Oestrogen 06.04.01.01 ESTRADIOL 100mcg patches Oestrogen 06.04.01.01 Estradiol 100micrograms/24hr once weekly patch Oestrogen 06.04.01.01 Ethinylestradiol 50microgram tablets Oestrogen 06.04.01.01 ESTRADIOL 75micrograms patches Oestrogen 06.04.01.01 ETHINYLOESTRADIOL 30 MCG TAB Oestrogen 06.04.01.01 Estradiol 50micrograms/24hr twice weekly patch Oestrogen Estradiol 25micrograms/24hours transdermal 06.04.01.01 patches Oestrogen 06.04.01.01 Dienestrol 5mg tablets Oestrogen Estradiol valerate and (estradiol valerate with levonorgestrel) 1mg with (1mg with 06.04.01.01 250micrograms) tablets Oestrogen 06.04.01.01 Estradiol 75micrograms/24hr twice weekly patch Oestrogen 06.04.01.01 Estradiol 75micrograms/24hr twice weekly patch Oestrogen 06.04.01.01 ESTRADIOL VALERATE 1mg tablets Oestrogen 06.04.01.01 ESTRADIOL 100mcg patches Oestrogen Estradiol 100micrograms/24hours transdermal 06.04.01.01 patches Oestrogen Conjugated oestrogens 1.25mg tablets and 06.04.01.01 Norgestrel 150microgram tablets Oestrogen Estradiol 25micrograms/24hours transdermal 06.04.01.01 patches Oestrogen 06.04.01.01 Estradiol 50micrograms/24hr twice weekly patch Oestrogen 06.04.01.01 Ethinylestradiol 10microgram tablets Oestrogen 06.04.01.01 ESTRADIOL 75micrograms patches Oestrogen 06.04.01.01 Estradiol 50mg implant Oestrogen 06.04.01.01 Estradiol 50micrograms/24hr twice weekly patch Oestrogen 06.04.01.01 Conjugated oestrogens 1.25mg tablets Oestrogen Estradiol 50micrograms/24hours / Levonorgestrel 06.04.01.01 7micrograms/24hours transdermal patches Oestrogen 06.04.01.01 ESTRADIOL VALERATE 2mg tablets Oestrogen
Load more

Recommended publications
  • Therapeutic Class Brand Name P a Status Generic
    P A Therapeutic Class Brand Name Status Generic Name Strength Form Absorbable Sulfonamides AZULFIDINE SULFASALAZINE 250MG/5ML ORAL SUSP Absorbable Sulfonamides AZULFIDINE SULFASALAZINE 500MG TABLET Absorbable Sulfonamides AZULFIDINE SULFASALAZINE 500MG TABLET DR Absorbable Sulfonamides BACTRIM DS SULFAMETHOXAZOLE/TRIMETHO 800-160MG TABLET Absorbable Sulfonamides GANTRISIN SULFISOXAZOLE 500MG TABLET Absorbable Sulfonamides GANTRISIN SULFISOXAZOLE ACETYL 500MG/5ML ORAL SUSP Absorbable Sulfonamides GANTRISIN SULFISOXAZOLE ACETYL 500MG/5ML SYRUP Absorbable Sulfonamides SEPTRA SULFAMETHOXAZOLE/TRIMETHO 200-40MG/5 ORAL SUSP Absorbable Sulfonamides SEPTRA SULFAMETHOXAZOLE/TRIMETHO 400-80MG TABLET Absorbable Sulfonamides SULFADIAZINE SULFADIAZINE 500MG TABLET ACE Inhibitor/Calcium Channel Blocker Combination LOTREL AMLODIPINE BESYLATE/BENAZ 10-20MG CAPSULE ACE Inhibitor/Calcium Channel Blocker Combination LOTREL AMLODIPINE BESYLATE/BENAZ 2.5-10MG CAPSULE ACE Inhibitor/Calcium Channel Blocker Combination LOTREL AMLODIPINE BESYLATE/BENAZ 5-10MG CAPSULE ACE Inhibitor/Calcium Channel Blocker Combination LOTREL AMLODIPINE BESYLATE/BENAZ 5-20MG CAPSULE P A Therapeutic Class Brand Name Status Generic Name Strength Form ACE Inhibitor/Calcium Channel Blocker Combination LOTREL AMLODIPINE BESYLATE/BENAZ 5-40MG CAPSULE ACE Inhibitor/Calcium Channel Blocker Combination LOTREL AMLODIPINE BESYLATE/BENAZ 10-40MG CAPSULE Acne Agents, Systemic ACCUTANE ISOTRETINOIN 10MG CAPSULE Acne Agents, Systemic ACCUTANE ISOTRETINOIN 20MG CAPSULE Acne Agents, Systemic ACCUTANE
    [Show full text]
  • 35 Cyproterone Acetate and Ethinyl Estradiol Tablets 2 Mg/0
    PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PrCYESTRA®-35 cyproterone acetate and ethinyl estradiol tablets 2 mg/0.035 mg THERAPEUTIC CLASSIFICATION Acne Therapy Paladin Labs Inc. Date of Preparation: 100 Alexis Nihon Blvd, Suite 600 January 17, 2019 St-Laurent, Quebec H4M 2P2 Version: 6.0 Control # 223341 _____________________________________________________________________________________________ CYESTRA-35 Product Monograph Page 1 of 48 Table of Contents PART I: HEALTH PROFESSIONAL INFORMATION ....................................................................... 3 SUMMARY PRODUCT INFORMATION ............................................................................................. 3 INDICATION AND CLINICAL USE ..................................................................................................... 3 CONTRAINDICATIONS ........................................................................................................................ 3 WARNINGS AND PRECAUTIONS ....................................................................................................... 4 ADVERSE REACTIONS ....................................................................................................................... 13 DRUG INTERACTIONS ....................................................................................................................... 16 DOSAGE AND ADMINISTRATION ................................................................................................ 20 OVERDOSAGE ....................................................................................................................................
    [Show full text]
  • The Progestogen Only Pill
    The Progestogen Only Pill Mini-pill or POP A service provided by page 2 of 8 How does the progestogen only pill (POP) work? The progestogen only pill mainly works by thickening the mucus you produce from your cervix. This makes it more difficult for sperm to get to the egg. It can also sometimes stop your ovaries from producing an egg (ovulation). How effective is the pill? The effectiveness of the pill depends on the woman taking it. At best it is over 98% effective (when no pills are missed). However failure rates can be much higher (9-15%) if women do not remember to take their pill properly. Missed pills can lead to pregnancy. Advantages of the POP • It doesn’t interfere with sex. • You can use it whilst you are breastfeeding. • It is useful if you cannot take oestrogen (the hormone contained in the combined oral contraceptive) • Can be used at any age even if you smoke and are over 35 years of age. • It may help with premenstrual symptoms and painful periods. page 3 of 8 Disadvantages of the POP • You have to remember to take your pill at the same time every day. • Your periods may become irregular or even stop altogether on the POP, this is not dangerous but if you miss a period you need to check that you are not pregnant by coming to clinic for a pregnancy test. • You may get some temporary side effects, such as spotty skin, breast tenderness and mood changes, though these should stop within a few months.
    [Show full text]
  • PEMD-91-12BR Off-Label Drugs: Initial Results of a National Survey
    11 1; -- __...._-----. ^.-- ______ -..._._ _.__ - _........ - t Ji Jo United States General Accounting Office Washington, D.C. 20648 Program Evaluation and Methodology Division B-242851 February 25,199l The Honorable Edward M. Kennedy Chairman, Committee on Labor and Human Resources United States Senate Dear Mr. Chairman: In September 1989, you asked us to conduct a study on reimbursement denials by health insurers for off-label drug use. As you know, the Food and Drug Administration designates the specific clinical indications for which a drug has been proven effective on a label insert for each approved drug, “Off-label” drug use occurs when physicians prescribe a drug for clinical indications other than those listed on the label. In response to your request, we surveyed a nationally representative sample of oncologists to determine: . the prevalence of off-label use of anticancer drugs by oncologists and how use varies by clinical, demographic, and geographic factors; l the extent to which third-party payers (for example, Medicare intermediaries, private health insurers) are denying payment for such use; and l whether the policies of third-party payers are influencing the treatment of cancer patients. We randomly selected 1,470 members of the American Society of Clinical Oncologists and sent them our survey in March 1990. The sam- pling was structured to ensure that our results would be generalizable both to the nation and to the 11 states with the largest number of oncologists. Our response rate was 56 percent, and a comparison of respondents to nonrespondents shows no noteworthy differences between the two groups.
    [Show full text]
  • Download PDF File
    Ginekologia Polska 2019, vol. 90, no. 9, 520–526 Copyright © 2019 Via Medica ORIGINAL PAPER / GYNECologY ISSN 0017–0011 DOI: 10.5603/GP.2019.0091 Anti-androgenic therapy in young patients and its impact on intensity of hirsutism, acne, menstrual pain intensity and sexuality — a preliminary study Anna Fuchs, Aleksandra Matonog, Paulina Sieradzka, Joanna Pilarska, Aleksandra Hauzer, Iwona Czech, Agnieszka Drosdzol-Cop Department of Pregnancy Pathology, Department of Woman’s Health, School of Health Sciences in Katowice, Medical University of Silesia, Katowice, Poland ABSTRACT Objectives: Using anti-androgenic contraception is one of the methods of birth control. It also has a significant, non-con- traceptive impact on women’s body. These drugs can be used in various endocrinological disorders, because of their ability to reduce the level of male hormones. The aim of our study is to establish a correlation between taking different types of anti-androgenic drugs and intensity of hirsutism, acne, menstrual pain intensity and sexuality . Material and methods: 570 women in childbearing age that had been using oral contraception for at least three months took part in our research. We examined women and asked them about quality of life, health, direct causes and effects of that treatment, intensity of acne and menstrual pain before and after. Our research group has been divided according to the type of gestagen contained in the contraceptive pill: dienogest, cyproterone, chlormadynone and drospirenone. Ad- ditionally, the control group consisted of women taking oral contraceptives without antiandrogenic component. Results: The mean age of the studied group was 23 years ± 3.23. 225 of 570 women complained of hirsutism.
    [Show full text]
  • CASODEX (Bicalutamide)
    HIGHLIGHTS OF PRESCRIBING INFORMATION • Gynecomastia and breast pain have been reported during treatment with These highlights do not include all the information needed to use CASODEX 150 mg when used as a single agent. (5.3) CASODEX® safely and effectively. See full prescribing information for • CASODEX is used in combination with an LHRH agonist. LHRH CASODEX. agonists have been shown to cause a reduction in glucose tolerance in CASODEX® (bicalutamide) tablet, for oral use males. Consideration should be given to monitoring blood glucose in Initial U.S. Approval: 1995 patients receiving CASODEX in combination with LHRH agonists. (5.4) -------------------------- RECENT MAJOR CHANGES -------------------------- • Monitoring Prostate Specific Antigen (PSA) is recommended. Evaluate Warnings and Precautions (5.2) 10/2017 for clinical progression if PSA increases. (5.5) --------------------------- INDICATIONS AND USAGE -------------------------- ------------------------------ ADVERSE REACTIONS ----------------------------- • CASODEX 50 mg is an androgen receptor inhibitor indicated for use in Adverse reactions that occurred in more than 10% of patients receiving combination therapy with a luteinizing hormone-releasing hormone CASODEX plus an LHRH-A were: hot flashes, pain (including general, back, (LHRH) analog for the treatment of Stage D2 metastatic carcinoma of pelvic and abdominal), asthenia, constipation, infection, nausea, peripheral the prostate. (1) edema, dyspnea, diarrhea, hematuria, nocturia, and anemia. (6.1) • CASODEX 150 mg daily is not approved for use alone or with other treatments. (1) To report SUSPECTED ADVERSE REACTIONS, contact AstraZeneca Pharmaceuticals LP at 1-800-236-9933 or FDA at 1-800-FDA-1088 or ---------------------- DOSAGE AND ADMINISTRATION ---------------------- www.fda.gov/medwatch The recommended dose for CASODEX therapy in combination with an LHRH analog is one 50 mg tablet once daily (morning or evening).
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • COVID-19—The Potential Beneficial Therapeutic Effects of Spironolactone During SARS-Cov-2 Infection
    pharmaceuticals Review COVID-19—The Potential Beneficial Therapeutic Effects of Spironolactone during SARS-CoV-2 Infection Katarzyna Kotfis 1,* , Kacper Lechowicz 1 , Sylwester Drozd˙ zal˙ 2 , Paulina Nied´zwiedzka-Rystwej 3 , Tomasz K. Wojdacz 4, Ewelina Grywalska 5 , Jowita Biernawska 6, Magda Wi´sniewska 7 and Miłosz Parczewski 8 1 Department of Anesthesiology, Intensive Therapy and Acute Intoxications, Pomeranian Medical University in Szczecin, 70-111 Szczecin, Poland; [email protected] 2 Department of Pharmacokinetics and Monitored Therapy, Pomeranian Medical University, 70-111 Szczecin, Poland; [email protected] 3 Institute of Biology, University of Szczecin, 71-412 Szczecin, Poland; [email protected] 4 Independent Clinical Epigenetics Laboratory, Pomeranian Medical University, 71-252 Szczecin, Poland; [email protected] 5 Department of Clinical Immunology and Immunotherapy, Medical University of Lublin, 20-093 Lublin, Poland; [email protected] 6 Department of Anesthesiology and Intensive Therapy, Pomeranian Medical University in Szczecin, 71-252 Szczecin, Poland; [email protected] 7 Clinical Department of Nephrology, Transplantology and Internal Medicine, Pomeranian Medical University, 70-111 Szczecin, Poland; [email protected] 8 Department of Infectious, Tropical Diseases and Immune Deficiency, Pomeranian Medical University in Szczecin, 71-455 Szczecin, Poland; [email protected] * Correspondence: katarzyna.kotfi[email protected]; Tel.: +48-91-466-11-44 Abstract: In March 2020, coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 was declared Citation: Kotfis, K.; Lechowicz, K.; a global pandemic by the World Health Organization (WHO). The clinical course of the disease is Drozd˙ zal,˙ S.; Nied´zwiedzka-Rystwej, unpredictable but may lead to severe acute respiratory infection (SARI) and pneumonia leading to P.; Wojdacz, T.K.; Grywalska, E.; acute respiratory distress syndrome (ARDS).
    [Show full text]
  • Hormonal Treatment Strategies Tailored to Non-Binary Transgender Individuals
    Journal of Clinical Medicine Review Hormonal Treatment Strategies Tailored to Non-Binary Transgender Individuals Carlotta Cocchetti 1, Jiska Ristori 1, Alessia Romani 1, Mario Maggi 2 and Alessandra Daphne Fisher 1,* 1 Andrology, Women’s Endocrinology and Gender Incongruence Unit, Florence University Hospital, 50139 Florence, Italy; [email protected] (C.C); jiska.ristori@unifi.it (J.R.); [email protected] (A.R.) 2 Department of Experimental, Clinical and Biomedical Sciences, Careggi University Hospital, 50139 Florence, Italy; [email protected]fi.it * Correspondence: fi[email protected] Received: 16 April 2020; Accepted: 18 May 2020; Published: 26 May 2020 Abstract: Introduction: To date no standardized hormonal treatment protocols for non-binary transgender individuals have been described in the literature and there is a lack of data regarding their efficacy and safety. Objectives: To suggest possible treatment strategies for non-binary transgender individuals with non-standardized requests and to emphasize the importance of a personalized clinical approach. Methods: A narrative review of pertinent literature on gender-affirming hormonal treatment in transgender persons was performed using PubMed. Results: New hormonal treatment regimens outside those reported in current guidelines should be considered for non-binary transgender individuals, in order to improve psychological well-being and quality of life. In the present review we suggested the use of hormonal and non-hormonal compounds, which—based on their mechanism of action—could be used in these cases depending on clients’ requests. Conclusion: Requests for an individualized hormonal treatment in non-binary transgender individuals represent a future challenge for professionals managing transgender health care. For each case, clinicians should balance the benefits and risks of a personalized non-standardized treatment, actively involving the person in decisions regarding hormonal treatment.
    [Show full text]
  • Comparing the Effects of Combined Oral Contraceptives Containing Progestins with Low Androgenic and Antiandrogenic Activities on the Hypothalamic-Pituitary-Gonadal Axis In
    JMIR RESEARCH PROTOCOLS Amiri et al Review Comparing the Effects of Combined Oral Contraceptives Containing Progestins With Low Androgenic and Antiandrogenic Activities on the Hypothalamic-Pituitary-Gonadal Axis in Patients With Polycystic Ovary Syndrome: Systematic Review and Meta-Analysis Mina Amiri1,2, PhD, Postdoc; Fahimeh Ramezani Tehrani2, MD; Fatemeh Nahidi3, PhD; Ali Kabir4, MD, MPH, PhD; Fereidoun Azizi5, MD 1Students Research Committee, School of Nursing and Midwifery, Department of Midwifery and Reproductive Health, Shahid Beheshti University of Medical Sciences, Tehran, Islamic Republic Of Iran 2Reproductive Endocrinology Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Islamic Republic Of Iran 3School of Nursing and Midwifery, Department of Midwifery and Reproductive Health, Shahid Beheshti University of Medical Sciences, Tehran, Islamic Republic Of Iran 4Minimally Invasive Surgery Research Center, Iran University of Medical Sciences, Tehran, Islamic Republic Of Iran 5Endocrine Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Islamic Republic Of Iran Corresponding Author: Fahimeh Ramezani Tehrani, MD Reproductive Endocrinology Research Center Research Institute for Endocrine Sciences Shahid Beheshti University of Medical Sciences 24 Parvaneh Yaman Street, Velenjak, PO Box 19395-4763 Tehran, 1985717413 Islamic Republic Of Iran Phone: 98 21 22432500 Email: [email protected] Abstract Background: Different products of combined oral contraceptives (COCs) can improve clinical and biochemical findings in patients with polycystic ovary syndrome (PCOS) through suppression of the hypothalamic-pituitary-gonadal (HPG) axis. Objective: This systematic review and meta-analysis aimed to compare the effects of COCs containing progestins with low androgenic and antiandrogenic activities on the HPG axis in patients with PCOS.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,555,168 B2 Browning (45) Date of Patent: *Jan
    USO09555168B2 (12) United States Patent (10) Patent No.: US 9,555,168 B2 Browning (45) Date of Patent: *Jan. 31, 2017 (54) SYSTEM FOR DELIVERY OF MEDICATION (58) Field of Classification Search IN TREATMENT OF DISORDERS OF THE None PELVIS See application file for complete search history. (71) Applicant: Coloplast A/S. Humlebaek (DK) (56) References Cited (72) Inventor: James Browning, Glasgow (GB) U.S. PATENT DOCUMENTS (73) Assignee: Coloplast A/S. Humlebaek (DK) 1450,101 A 3, 1923 Mathewson 2,097,018 A 10, 1937 Chamberlin (*) Notice: Subject to any disclaimer, the term of this 2.427,176 A 9, 1947 Aldeen 2,738,790 A 3/1956 Todt, Sr. et al. patent is extended or adjusted under 35 3,054,406 A 9, 1962 Usher U.S.C. 154(b) by 0 days. 3,124,136 A 3, 1964 Usher 3,126,600 A 3, 1964 De Marre This patent is Subject to a terminal dis 3,182,662 A 5, 1965 Shirodkar claimer. 3,311,110 A 3/1967 Singerman et al. 3,384,073. A 5/1968 Van Winkle, Jr. (21) Appl. No.: 15/131,043 3,472,232 A 10, 1969 Pendleton 3,580,313 A 5/1971 McKnight 3,763,860 A 10, 1973 Clarke (22) Filed: Apr. 18, 2016 3,789,828 A 2f1974 Schulte 3,858,783 A 1/1975 Kapitanov et al. (65) Prior Publication Data 3,888.975 A 6, 1975 Ramwell 3,911,911 A 10/1975 Scommegna US 2016/0228620 A1 Aug. 11, 2016 3,913, 179 A 10, 1975 Rhee Related U.S.
    [Show full text]
  • Estradiol Acetate Vaginal Ring) Rx Only
    NDA 21-367/S-002 Page 3 PRESCRIBING INFORMATION Femring® (estradiol acetate vaginal ring) Rx Only ESTROGENS INCREASE THE RISK OF ENDOMETRIAL CANCER Close clinical surveillance of all women taking estrogens is important. Adequate diagnostic measures, including endometrial sampling when indicated, should be undertaken to rule out malignancy in all cases of undiagnosed persistent or recurring abnormal vaginal bleeding. There is no evidence that the use of “natural” estrogens results in a different endometrial risk profile than synthetic estrogens at equivalent estrogen doses. (See WARNINGS, Malignant neoplasms, Endometrial cancer.) CARDIOVASCULAR AND OTHER RISKS Estrogens with or without progestins should not be used for the prevention of cardiovascular disease or dementia. (See WARNINGS, Cardiovascular disorders and Dementia.) The Women’s Health Initiative (WHI) study reported increased risks of myocardial infarction, stroke, invasive breast cancer, pulmonary emboli, and deep vein thrombosis in postmenopausal women (50 to 79 years of age) during 5 years of treatment with oral conjugated estrogens (CE 0.625 mg) combined with medroxyprogesterone acetate (MPA 2.5 mg) relative to placebo. (See CLINICAL PHARMACOLOGY, Clinical Studies and WARNINGS, Cardiovascular disorders and Malignant neoplasms, Breast cancer.) The Women’s Health Initiative Memory Study (WHIMS), a substudy of WHI, reported increased risk of developing probable dementia in postmenopausal women 65 years of age or older during 4 years of treatment with oral conjugated estrogens
    [Show full text]